Clinical Trial Update: Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating reduced-intensity conditioning with fludarabine and melphalan plus total body irradiation for haploidentical stem cell transplantation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Myelodysplastic Syndromes

Drugs mentioned

• Alkeran (melphalan)
• Fludara (fludarabine)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2025-03-07